Overview

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2016-12-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish proof of concept and identify the optimal efficacious dose for namilumab in RA in patients with an inadequate response to methotrexate (MTX-IR) and in patients with an inadequate response to one tumor necrosis factor (TNF)-inhibitor (TNF-IR).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Folic Acid
Leucovorin
Levoleucovorin
Methotrexate